The new US-UK drug deal will reduce medicine prices by up to 20% and speed up patient access by six months, according to a joint statement from the US Department of Health and Human Services and the UK Department of Health and Social Care.
Key provisions of the agreement
The deal, signed on Monday, creates a mutual recognition framework for pharmaceutical approvals. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) will share clinical trial data and inspection reports, cutting duplication. The agreement covers new drugs, biologics, and generics, but excludes medical devices and vaccines for now.
Under the terms, the MHRA will accept FDA-approved drugs for UK marketing without additional trials, provided the FDA has inspected the manufacturing site. Similarly, the FDA will fast-track British-developed medicines. The deal is expected to cut average drug approval times from 12 months to six months in the UK, and from 10 months to four months in the US.
Price reductions for patients
The UK government estimates that NHS medicines spending will fall by £1.2 billion over five years due to lower prices negotiated through joint procurement. US patients will see savings through increased competition and lower administrative costs. The deal also includes a commitment to cap annual price increases at inflation plus 2% for essential medicines.
"This is a landmark agreement that will put patients first," said UK Health Secretary Wes Streeting. "By working with our American partners, we can deliver cheaper medicines faster while maintaining the highest safety standards."
Industry reaction and next steps
Pharmaceutical companies have welcomed the deal, with the Association of the British Pharmaceutical Industry (ABPI) calling it "a win for patients and innovation." However, some patient groups have raised concerns about potential regulatory capture and reduced safety oversight. The deal will be implemented in phases, starting with cancer treatments and rare disease drugs from January 2027.
"This agreement will transform access to life-saving treatments," said FDA Commissioner Dr. Robert Califf. "It demonstrates that strong regulatory collaboration can benefit patients on both sides of the Atlantic."
